Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015
A webcast of the presentation will be accessible under Events & Presentations in the Investors section of www.avalanchebiotech.com. Avalanche will maintain an archived replay of the webcast on its website for at least two weeks.
Breakfast and Registration:
Program and Webcast:
Jean Bennett M.D., Ph.D., Professor, Ophthalmology; Director, Center for Advanced Retinal and Ocular Therapeutics(CAROT), University of Pennsylvania Perelman School of Medicine
David Brown, M.D., Retina Consultantsof Houston; Clinical Professor of Ophthalmology, Baylor College of Medicine
Jeffrey S. Heier, M.D., Director of Vitreoretinal Service, Ophthalmic Consultantsof Boston
Szilárd Kiss, M.D., Director of Clinical Research and Associate Professor of Ophthalmology,
Weill Cornell Medical College
Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with a clear unmet medical need. Avalanche's proprietary Ocular BioFactory™ is a platform for discovering and developing novel medicines with the potential to offer life-changing therapeutic benefit. Avalanche's lead product candidate, AVA-101, is in mid-stage clinical development for patients with wet age-related macular degeneration. For more information, please visit www.avalanchebiotech.com.
CONTACT: Investor Contact
Lauren Glaser(650) 656-9347 firstname.lastname@example.org Media Contact Carolyn Wang(415) 946-1065 email@example.com